In summary, we demonstrate that CD4+ T cells and CD19+ B cells are comparably decreased in all fingolimod treated patients whereas grade of lymphopenia is primarily defined by individual variation of CD8+ T cell and NK cells. This evidence concerns the gene CD8A and lymphopenia.